Atul Dandekar, an officer of Maze Therapeutics, Inc., filed a Form 144 notice on October 29, 2026, disclosing a proposed sale of 15,000 shares of common stock on NASDAQ under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Proposed sale: Atul Dandekar, listed as an officer, intends to sell 15,000 shares of Maze Therapeutics common stock with an aggregate market value of $475,950.00.
  • Source of shares: The shares are to be acquired through the exercise of stock options from the issuer, with an acquisition date of 10/29/2026.
  • Approximate sale date: The filing lists the approximate date of sale as 10/29/2026 on NASDAQ.
  • Shares outstanding: According to the filing, 55,549,168 shares of common stock were outstanding at the time of the notice.
  • Prior sales in past 3 months: Dandekar sold 7,500 shares on 09/29/2026 for gross proceeds of $202,920.75, and 7,500 shares on 08/28/2026 for gross proceeds of $206,823.75, both under a 10b5-1 plan.
  • Rule 10b5-1 plan: The filing indicates a trading plan was adopted on 09/29/2025.

Dandekar's Proposed Stock Option Exercise and Sale at Maze Therapeutics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Atul Dandekar, an officer of Maze Therapeutics, Inc. (NASDAQ:MAZE), proposed the sale of 15,000 shares of the company's common stock. The filing states that the securities "were and will be received upon the exercise of stock options over the next three months," and that "the dates of acquisition and payment were and will be the dates of exercise/sale." The broker named in the filing is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing discloses that Dandekar sold a combined 15,000 shares over the two months prior to this notice: 7,500 shares on 09/29/2026 generating gross proceeds of $202,920.75, and another 7,500 shares on 08/28/2026 generating gross proceeds of $206,823.75. Both prior sales are attributed to 10b5-1 plan activity. The current proposed sale of 15,000 shares carries an aggregate market value of $475,950.00 as stated in the filing, against a total of 55,549,168 shares of common stock outstanding.

The filing reflects that the Rule 10b5-1 trading plan underlying these transactions was adopted on 09/29/2025. Maze Therapeutics, Inc. is headquartered at 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080, and carries SEC File Number 001-42490.

What Was Disclosed

Maze Therapeutics officer Atul Dandekar filed a Form 144 notice on 10/29/2026, disclosing a proposed sale of 15,000 shares of common stock valued at $475,950.00, to be acquired via stock option exercise, alongside prior 10b5-1 plan sales totaling 15,000 shares over the preceding two months.